Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:
  • Suspended  
  • Page 1 ·  Next »

NCT ID: NCT03050346 Suspended - Clinical trials for Coronary Artery Disease

Breathing-Induced Myocardial Oxygenation Reserve

B-MORE-Pilot
Start date: January 2016
Phase:
Study type: Observational

This is a clinical trial to test the clinical feasibility and safety of a novel CMR protocol, combined with a specific breathing maneuver to identify myocardial regions exposed to severe coronary artery stenosis.

NCT ID: NCT02916485 Suspended - Clinical trials for Coronary Artery Disease

Safety and Clinical Performance of a Sirolimus-eluting Absorbable Metal Scaffold

BIOSOLVE-India
Start date: June 2017
Phase: N/A
Study type: Interventional

Assessment of the clinical performance and the safety of the Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold in a cohort of patients in India with de novo coronary artery lesions.

NCT ID: NCT02561000 Suspended - Clinical trials for Coronary Artery Disease

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

TRIP-PCI
Start date: May 27, 2016
Phase: Phase 2
Study type: Interventional

The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding. A secondary objective is to determine whether patients treated with PZ-128 have fewer cardiac events such as heart attack, bypass surgery or stroke compared with those persons treated with the standard of care.

NCT ID: NCT02474485 Suspended - Clinical trials for Coronary Artery Disease

Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR

AbsorbISR
Start date: March 2015
Phase: N/A
Study type: Interventional

AbsorbISR is a randomized, controlled trial, single center, prospective, not blinded to evaluate two strategies of in stent restenosis treatment: Implantation of drug eluting bioresorbable stent scaffold Absorb® vs. balloon angioplasty with drug eluting balloon Sequent Please®.

NCT ID: NCT02472002 Suspended - Coronary Disease Clinical Trials

Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients

MESHT
Start date: January 2014
Phase: Phase 1/Phase 2
Study type: Interventional

MES-HT is a pilot multicenter prospective study conducted in transplant patients who developed severe coronary vasculopathy. A preparation of autologous mesenchymal cells of bone marrow is administered by endomyocardial injection, guided by the Noga® cardiac mapping system. The main objective is to determine the effect of the administration of autologous mesenchymal cells of the bone marrow by intramyocardial injection on myocardial perfusion in cardiac transplant patients with severe coronary vasculopathy.

NCT ID: NCT02468778 Suspended - Clinical trials for Coronary Artery Disease

Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)

SHIELD II
Start date: August 2015
Phase: N/A
Study type: Interventional

The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction.

NCT ID: NCT01740739 Suspended - Clinical trials for Coronary Artery Disease

Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors

Cardiac-CV
Start date: November 2012
Phase: N/A
Study type: Observational

The objective of this study is to explore the relationship between the ClearView scan results and a variety of cardiovascular risk indicators such as the Coronary Calcium Score, Framingham Risk Factors, Reynolds Risk Score, and biomarkers of inflammation. The ClearView device is a bio-electrographic tool that may assist medical professionals in rapid assessment of the systemic origin of the patient's presenting symptom(s). The ClearView is a potentially valuable resource that may benefit a physician's office by offering expedited differentiation capabilities. The subsequent results have the potential to include more data that would allow rapid patient diagnosis, triage, and treatment; optimized precious resource expenditure (nursing, physician, etc.); lower costs to facility, patient and insurance company; and decreased office wait time.

NCT ID: NCT01655524 Suspended - Clinical trials for Coronary Artery Disease

The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion

ASSUAGE-MPI
Start date: July 2012
Phase: Phase 4
Study type: Interventional

The investigators developed a modified regadenoson nuclear stress test of the heart that incorporates an aminophylline injection following regadenoson (The ASSUAGE protocol). The modified (ASSUAGE) protocol has been associated with fewer side effects and was better tolerated by patients. This study will investigate whether the modified regadenoson stress protocol (ASSUAGE) produces blood flow pattern to the heart similar to that of a standard regadenoson stress protocol. In proven to be the case, the ASSUAGE protocol has the potential to be used on a wide scale instead of the current standard protocol.

NCT ID: NCT00929227 Suspended - Clinical trials for Coronary Artery Disease

Comparison of Cardiac Computed Tomography and Vasodilator Stress Magnetic Resonance Imaging Perfusion in Patients With Prior Equivocal Stress Test for Detection of Coronary Artery Disease

Start date: June 24, 2009
Phase:
Study type: Observational

Background: - Noninvasive cardiac stress testing is imperfect. Inconclusive test results generate further expensive testing. - In patients with known or suspected coronary artery disease, both computed tomography (CT) and magnetic resonance imaging (MRI) have been shown to provide suitable results for detecting the disease. However, both types of scans have limitations in their usefulness, and it is not known whether one is preferable in either accuracy or cost-effectiveness. Objectives: - To determine the accuracy and cost-effectiveness of CT and MRI in subjects with a prior inconclusive heart stress test. Eligibility: - Patients 18 years of age and older who have had an inconclusive heart stress test within the past 90 days. Design: - A blood test will be obtained prior to both heart tests. This will require less than a teaspoon of blood. - A CT scan will be performed, accompanied by beta blocker medications (to slow heart rate) or nitroglycerin (to enlarge blood vessels) to improve picture quality, as needed. - An MRI scan will be performed. Scans will be taken before, during, and after the patient receives vasodilators (to increase blood flow to the coronary arteries and detect blockages in heart blood vessels). - Heart rate and function will be monitored with an electrocardiogram.

NCT ID: NCT00790764 Suspended - Clinical trials for Coronary Artery Disease

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The present investigation will be a Phase II, single center, placebo-controlled, randomized, dose escalation, infusion modality (intracoronary vs transendocardial injection using the Cordis Biosense NOGASTAR TM Mapping Catheter with the Biosense MYOSTAR TM left ventricular injection catheter) transplantation of an autologous (your own stem cells) combination of bone marrow-derived stem cells into myocardium for the treatment of severe coronary ischemia. The purpose of this research study is to determine if the infusion of a combination of stem cells obtained from the bone marrow of the same patient will contribute to the formation of new blood vessels in patients with symptomatic severe coronary ischemia(CI). In this trial we will determine whether the combination stem cell treatment is safe, feasible and results in the development of mature stable and/or collateral vessels and improvement of cardiac function. Coronary Ischemia (CI) is intractable angina due to severe coronary artery disease which can seriously decrease blood flow to the heart. CI needs a comprehensive treatment since the condition will not improve on its own. The overall goal of the treatment is to increase blood flow to the heart and improve symptoms of angina. The study hypothesis is based on the concept that the process of formation of new blood vessels is complex and requires the participation of several types of stem cells and growth factors. The lack of any of these components will produce vessels which are immature and unable to provide appropriate blood supply to the heart. Patients eligible to participate in this study are those suffering from severe blockages of the vessels of the heart and are not candidates for percutaneous revascularization or surgical procedures.